SOURCE: The Bedford Report

The Bedford Report

May 10, 2011 08:16 ET

Sequenom and OXiGENE Optimistic About Future Growth Prospects

The Bedford Report Provides Analyst Research on Sequenom and OXiGENE

NEW YORK, NY--(Marketwire - May 10, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Sequenom, Inc. (NASDAQ: SQNM) and OXiGENE, Inc. (NASDAQ: OXGN). Access to the full company reports can be found at:

www.bedfordreport.com/2011-05-SQNM

www.bedfordreport.com/2011-05-OXGN

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Last week shares of Sequenom surged after the company said it had completed testing of samples for its new prenatal Down syndrome test. Sequenom also reported a quarterly loss of 13 cents a share, compared with a loss of 27 cents a share for the year-ago period.

Recent studies have shown that the chances of FDA approval for early stage drugs is dropping significantly, with medication designed to treat cancer being one of the least likely to receive regulatory authorization. OXiGENE, a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, is hoping to be an exception to that statistic with its product, ZYBRESTAT. ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell lung cancer and other clinical trials.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.

Contact Information